Moxonidine
- Generic Name
- Moxonidine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C9H12ClN5O
- CAS Number
- 75438-57-2
- Unique Ingredient Identifier
- CC6X0L40GW
- Background
Moxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild to moderate essential hypertension. It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive. As well, moxonidine has been shown to prese...
- Indication
For the treatment of mild to moderate essential or primary hypertension . Effective as most first-line antihypertensives when used as monotherapy .
- Associated Conditions
- Hypertension
- Associated Therapies
- -
Sympathetic Mechanisms in Obesity-Crossover Design
- Conditions
- Interventions
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 12
- Registration Number
- NCT05312892
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Moxonidine Effects on Neuropeptide Y
- First Posted Date
- 2021-12-07
- Last Posted Date
- 2021-12-07
- Lead Sponsor
- Aristotle University Of Thessaloniki
- Target Recruit Count
- 90
- Registration Number
- NCT05147753
Autonomic Determinants of POTS - Pilot1
- Conditions
- Interventions
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 48
- Registration Number
- NCT04050410
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Comparative Effects of Moxonidine on Bone Metabolism, Vascular and Cellular Aging in Hypertensive Postmenopausal Women
- Conditions
- Interventions
- First Posted Date
- 2015-02-04
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- National Research Center for Preventive Medicine
- Target Recruit Count
- 114
- Registration Number
- NCT02355821
- Locations
- 🇷🇺
National Research Center for Preventive Medicine, Moscow, Russian Federation
Moxonidine for Prevention of Post-ablation AFib Recurrences
- First Posted Date
- 2013-02-15
- Last Posted Date
- 2014-05-06
- Lead Sponsor
- Spyridon Deftereos
- Target Recruit Count
- 150
- Registration Number
- NCT01791699
- Locations
- 🇬🇷
Red Cross Hospital, Athens, Greece
🇬🇷Evangelismos General Hospital, Athens, Greece
🇬🇷Athens General Hospital "G. Gennimatas", Athens, Greece
Alleviating the Metabolic Side Effects of Antipsychotic Medications
- First Posted Date
- 2012-03-30
- Last Posted Date
- 2019-04-24
- Lead Sponsor
- Baker Heart and Diabetes Institute
- Registration Number
- NCT01567124
- Locations
- 🇦🇺
Ballarat Health Service Psychiatric Services, Ballarat, Victoria, Australia
🇦🇺Alfred and Baker Medical Unit - Alfred Hospital, Melbourne, Victoria, Australia
🇦🇺Baker IDI Heart & Diabetes Institute, Melbourne, Victoria, Australia
Polycystic Ovary Syndrome - Improving Outcomes
- First Posted Date
- 2012-01-05
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- Baker Heart and Diabetes Institute
- Target Recruit Count
- 42
- Registration Number
- NCT01504321
- Locations
- 🇦🇺
Heart Centre, Alfred Hospital, Prahran, Victoria, Australia
The Effect of Moxonidine on Blood Pressure and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension
- First Posted Date
- 2011-05-26
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Baker Heart and Diabetes Institute
- Target Recruit Count
- 100
- Registration Number
- NCT01360710
- Locations
- 🇦🇺
BakerIDI Heart and Diabetes Institute, Prahran, Victoria, Australia
Treatment of Adiposity Related hypErTension (TARGET)
- First Posted Date
- 2010-06-07
- Last Posted Date
- 2012-02-24
- Lead Sponsor
- UMC Utrecht
- Target Recruit Count
- 32
- Registration Number
- NCT01138423
- Locations
- 🇳🇱
UMC Utrecht, Utrecht, Netherlands
Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease
- First Posted Date
- 2010-03-29
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Baker Heart and Diabetes Institute
- Target Recruit Count
- 48
- Registration Number
- NCT01094769
- Locations
- 🇦🇺
Alfred & Baker Medical Unit, Melbourne, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.